Skip to content

Advertisement

Articles

Page 4 of 33

  1. Content type: Research article

    Tumor-derived autophagosome vaccines (DRibbles) have the potential to broaden immune response to poorly immunogenic tumors.

    Authors: Rachel E. Sanborn, Helen J. Ross, Sandra Aung, Anupama Acheson, Tarsem Moudgil, Sachin Puri, Traci Hilton, Brenda Fisher, Todd Coffey, Christopher Paustian, Michael Neuberger, Edwin Walker, Hong-Ming Hu, Walter J. Urba and Bernard A. Fox

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:103

    Published on:

  2. Content type: Research article

    Myeloid cells are an abundant leukocyte in many types of tumors and contribute to immune evasion. Expression of the enzyme arginase 1 (Arg1) is a defining feature of immunosuppressive myeloid cells and leads t...

    Authors: Susanne M. Steggerda, Mark K. Bennett, Jason Chen, Ethan Emberley, Tony Huang, Julie R. Janes, Weiqun Li, Andrew L. MacKinnon, Amani Makkouk, Gisele Marguier, Peter J. Murray, Silinda Neou, Alison Pan, Francesco Parlati, Mirna L. M. Rodriguez, Lee-Ann Van de Velde…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:101

    Published on:

  3. Content type: Research article

    We have previously shown that radiotherapy (RT) augments natural killer (NK) functions in pre-clinical models of human and mouse cancers, including sarcomas. Since dogs are an excellent outbred model for immun...

    Authors: Robert J. Canter, Steven K. Grossenbacher, Jennifer A. Foltz, Ian R. Sturgill, Jiwon S. Park, Jesus I. Luna, Michael S. Kent, William T. N. Culp, Mingyi Chen, Jaime F. Modiano, Arta M. Monjazeb, Dean A. Lee and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:98

    Published on:

  4. Content type: Research article

    Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact ...

    Authors: Brendan Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy Gregory, Michael A. Morse, Michael K. K. Wong and Janice P. Dutcher

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:102

    Published on:

  5. Content type: Research article

    Programmed cell death ligand-1 (PD-L1) expression has been reported in up to 61% of high grade gliomas (HGG). The purpose of this study was to describe safety and efficacy of PD-1 inhibition in patients with r...

    Authors: Samantha N. Reiss, Prakirthi Yerram, Lisa Modelevsky and Christian Grommes

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:99

    Published on:

  6. Content type: Case report

    There has been a significant improvement in survival of advanced malignancies with the advent of checkpoint inhibitors. These newer treatment modalities come with a wide spectrum of unique side effects, termed...

    Authors: Pouyan N. Changizzadeh, Shiva Kumar R. Mukkamalla and Vincent A. Armenio

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:97

    Published on:

  7. Content type: Research article

    Hepatocellular carcinoma (HCC) is a major health problem worldwide with increasing incidence rates. As HCC traditionally occurs in chronically inflamed livers, this inflammation aids to drive oncogenesis and o...

    Authors: Zachary J. Brown, Bernd Heinrich, Seth M. Steinberg, Su Jong Yu and Tim F. Greten

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:93

    Published on:

  8. Content type: Research article

    Breast cancer remains a leading cause of cancer death worldwide. There is evidence that immunotherapy may play a role in the eradication of residual disease. Peptide vaccines for immunotherapy are capable of d...

    Authors: Patrick M. Dillon, Gina R. Petroni, Mark E. Smolkin, David R. Brenin, Kimberly A. Chianese-Bullock, Kelly T. Smith, Walter C. Olson, Ibrahim S. Fanous, Carmel J. Nail, Christiana M. Brenin, Emily H. Hall and Craig L. Slingluff Jr

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:92

    Published on:

  9. Content type: Review

    With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic optio...

    Authors: Adam Ajina and John Maher

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:90

    Published on:

  10. Content type: Research article

    Checkpoint blockade with ipilimumab provides long-term survival to a significant proportion of patients with metastatic melanoma. New approaches to increase survival and to predict which patients will benefit ...

    Authors: Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis, Paméla Thébault, Shirin Kazemi, Jennifer E. Friedmann, Jeanne Dionne, Jean-François Cailhier, Karl Bélanger, Jean-Pierre Ayoub, Huy Le, Caroline Lambert, Jida El-Hajjar, Léon C. van Kempen, Alan Spatz and Wilson H. Miller Jr

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:83

    Published on:

  11. Content type: Review

    Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for...

    Authors: David H. Aggen and Charles G. Drake

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:94

    Published on:

  12. Content type: Position article and guidelines

    Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a d...

    Authors: I. Puzanov, A. Diab, K. Abdallah, C. O. Bingham III, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. E. Lacouture, N. R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. W. Silk, D. Skondra…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:95

    Published on:

  13. Content type: Research article

    It remains challenging to characterize the functional attributes of chimeric antigen receptor (CAR)-engineered T cell product targeting CD19 related to potency and immunotoxicity ex vivo, despite promising in ...

    Authors: Qiong Xue, Emily Bettini, Patrick Paczkowski, Colin Ng, Alaina Kaiser, Timothy McConnell, Olja Kodrasi, Máire F. Quigley, James Heath, Rong Fan, Sean Mackay, Mark E. Dudley, Sadik H. Kassim and Jing Zhou

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:85

    Published on:

  14. Content type: Case report

    Metastatic gastric cancer (GC) is an incurable and aggressive disease with a poor prognosis. Immunotherapy is an attractive approach for treating patients with cancer, and studies using immunotherapy have show...

    Authors: Gustavo dos Santos Fernandes, Daniel da Motta Girardi, Luiza Dib Batista Bugiato Faria, João Paulo Giacomini Bernardes and Renata de Almeida Coudry

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:84

    Published on:

  15. Content type: Case report

    Severe myocarditis associated with electrical conduction abnormalities and occasionally heart failure has been well documented following treatment with immune checkpoint blockade with an estimated incidence of...

    Authors: Timothy G. Norwood, Brian C. Westbrook, Douglas B. Johnson, Silvio H. Litovsky, Nina L. Terry, Svetlana B. McKee, Alan S. Gertler, Javid J. Moslehi and Robert M. Conry

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:91

    Published on:

  16. Content type: Correction

    Authors: Veronika Kremer, Maarten A. Ligtenberg, Rosa Zendehdel, Christina Seitz, Annet Duivenvoorden, Erik Wennerberg, Eugenia Colón, Ann-Helén Scherman-Plogell and Andreas Lundqvist

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:88

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2017 5:73

  17. Content type: Review

    Metastatic disease is the leading cause of death among cancer patients and involves a complex and inefficient process. Every step of the metastatic process can be rate limiting and is influenced by non-maligna...

    Authors: Louise M.E. Janssen, Emma E. Ramsay, Craig D. Logsdon and Willem W. Overwijk

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:79

    Published on:

  18. Content type: Research article

    Immunostimulatory therapies targeting immune-suppressive pathways produce durable responses in advanced solid tumors. Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting oxidoreductase that catalyzes the de...

    Authors: Daniel E. Carvajal-Hausdorf, Nikita Mani, Vamsidhar Velcheti, Kurt A. Schalper and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:81

    Published on:

  19. Content type: Review

    The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particula...

    Authors: Ryan Slovak, Johannes M. Ludwig, Scott N. Gettinger, Roy S. Herbst and Hyun S. Kim

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:78

    Published on:

  20. Content type: Research Article

    Brain metastases are common in patients with metastatic melanoma. With increasing numbers of melanoma patients on anti-PD-1 therapy, we sought to evaluate the safety and initial response of brain metastases tr...

    Authors: Erik S. Anderson, Michael A. Postow, Jedd D. Wolchok, Robert J. Young, Åse Ballangrud, Timothy A. Chan, Yoshiya Yamada and Kathryn Beal

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:76

    Published on:

  21. Content type: Research article

    There is an unmet need to determine factors predictive of clinical benefit, to guide therapeutic sequencing and selection in metastatic RCC (mRCC). We evaluated clinical factors such as the neutrophil lymphocy...

    Authors: Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth Heath, Joseph Fontana and Ulka Vaishampayan

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:82

    Published on:

  22. Content type: Erratum

    Authors: Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor III, Prasanth Abraham…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:80

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2017 5:68

  23. Content type: Research article

    Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% ...

    Authors: Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood and Hussein A. Tawbi

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:74

    Published on:

  24. Content type: Research article

    Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [comple...

    Authors: Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov and Merrick Ross

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:72

    Published on:

  25. Content type: Meeting report

    Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Soc...

    Authors: Andrew Zloza, A. Karolina Palucka, Lisa M. Coussens, Philip J. Gotwals, Mark B. Headley, Elizabeth M. Jaffee, Amanda W. Lund, Arlene H. Sharpe, Mario Sznol, Derek A. Wainwright, Kwok-Kin Wong and Marcus W. Bosenberg

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:77

    Published on:

  26. Content type: Research article

    Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in co...

    Authors: Caroline Tosch, Bérangère Bastien, Luc Barraud, Benoit Grellier, Virginie Nourtier, Murielle Gantzer, Jean Marc Limacher, Eric Quemeneur, Kaïdre Bendjama and Xavier Préville

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:70

    Published on:

  27. Content type: Research article

    Adoptive natural killer (NK) cell transfer is being increasingly used as cancer treatment. However, clinical responses have so far been limited to patients with hematological malignancies. A potential limiting...

    Authors: Veronika Kremer, Marteen A. Ligtenberg, Rosa Zendehdel, Christina Seitz, Annet Duivenvoorden, Erik Wennerberg, Eugenia Colón, Ann-Helén Scherman-Plogell and Andreas Lundqvist

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:73

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:88

  28. Content type: Research article

    Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in...

    Authors: Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Juan M. Bozada, Valentina Boni, Christine Blanc, Len Seymour, John Beadle, Simon Alvis, Brian Champion, Emiliano Calvo and Kerry Fisher

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:71

    Published on:

  29. Content type: Case report

    Large cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive tumor similar to small cell lung cancer (SCLC). Thus, it is often treated similarly to SCLC in the front-line setting with a platinu...

    Authors: Victoria E. Wang, Anatoly Urisman, Lee Albacker, Siraj Ali, Vincent Miller, Rahul Aggarwal and David Jablons

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:75

    Published on:

  30. Content type: Research article

    Colorectal cancer is responsible for almost 700,000 deaths annually worldwide. Therapeutic vaccination is a promising alternative to conventional treatment for colorectal cancer, using vaccines to induce targe...

    Authors: Braeden Donaldson, Farah Al-Barwani, Simon J. Pelham, Katie Young, Vernon K. Ward and Sarah L. Young

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:69

    Published on:

  31. Content type: Research article

    The suppressive nature of immune cells in the tumor microenvironment plays a major role in regulating anti-tumor immune responses. Our previous work demonstrated that a soluble factor from tumor cells is able ...

    Authors: Brian T. Maybruck, Lukas W. Pfannenstiel, Marcela Diaz-Montero and Brian R. Gastman

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:65

    Published on:

  32. Content type: Research article

    Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to...

    Authors: Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj and William K. Oh

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:67

    Published on:

  33. Content type: Research article

    T-cell checkpoint blockade and MEK inhibitor combinations are under clinical investigation. Despite progress elucidating the immuno-modulatory effects of MEK inhibitors as standalone therapies, the impact of M...

    Authors: Edmund Poon, Stefanie Mullins, Amanda Watkins, Geoffrey S. Williams, Jens-Oliver Koopmann, Gianfranco Di Genova, Marie Cumberbatch, Margaret Veldman-Jones, Shaun E. Grosskurth, Vasu Sah, Alwin Schuller, Corrine Reimer, Simon J. Dovedi, Paul D. Smith, Ross Stewart and Robert W. Wilkinson

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:63

    Published on:

  34. Content type: Position Article and Guidelines

    The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and dest...

    Authors: Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor III, Prasanth Abraham…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:68

    Published on:

    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:80

  35. Content type: Research article

    We previously demonstrated that in addition to generating an antigen-specific immune response, Listeria monocytogenes (Lm)-based immunotherapy significantly reduces the ratio of regulatory T cells (Tregs)/CD4+ an...

    Authors: Rajeev Shrimali, Shamim Ahmad, Zuzana Berrong, Grigori Okoev, Adelaida Matevosyan, Ghazaleh Shoja E. Razavi, Robert Petit, Seema Gupta, Mikayel Mkrtichyan and Samir N. Khleif

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:64

    Published on:

  36. Content type: Case report

    Renal medullary carcinoma is one of the rarest malignancies arising from the kidney. Despite various aggressive therapeutic regimens, mortality remains significantly high (95%) with a median overall survival o...

    Authors: Quaovi Sodji, Kandy Klein, Kavuri Sravan and Jigarkumar Parikh

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:62

    Published on:

  37. Content type: Case report

    Monoclonal antibodies targeting the PD-1/PD-L1 axis have gained increasing attention across many solid tumors and hematologic malignancies due to their efficacy and favorable toxicity profile. With more than 1...

    Authors: Dylan J. Martini, Aly-Khan A. Lalani, Dominick Bossé, John A. Steinharter, Lauren C. Harshman, F. Stephen Hodi, Patrick A. Ott and Toni K. Choueiri

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:66

    Published on:

  38. Content type: Research article

    Immunotherapies have demonstrated clinical benefit for many types of cancers, however many patients do not respond, and treatment-related adverse effects can be severe. Hence many efforts are underway to ident...

    Authors: Laura E. Johnson, Brian M. Olson and Douglas G. McNeel

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:56

    Published on:

  39. Content type: Review

    Therapeutic efforts to engage the immune system against cancer have yielded exciting breakthroughs and a growing list of approved immune-based agents across a variety of disease states. Despite the early succe...

    Authors: James L. Gulley, Elizabeth A. Repasky, Laura S. Wood and Lisa H. Butterfield

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:55

    Published on:

  40. Content type: Review

    The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 ...

    Authors: Michael A. Cannarile, Martin Weisser, Wolfgang Jacob, Anna-Maria Jegg, Carola H. Ries and Dominik Rüttinger

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:53

    Published on:

  41. Content type: Case report

    The anti-Programmed Death receptor 1 (anti-PD-1) antibodies nivolumab and pembrolizumab are new treatments in metastatic melanoma. Immunotherapies are best known to be responsible for thrombotic microangiopath...

    Authors: Lea Bottlaender, Anne-Laure Breton, Louis de Laforcade, Frederique Dijoud, Luc Thomas and Stephane Dalle

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:57

    Published on:

  42. Content type: Case report

    Angiosarcomas are tumors of malignant endothelial origin that have a poor prognosis with a five-year survival of less than 40%. These tumors can be found in all age groups, but are more common in older patient...

    Authors: Simran Sindhu, Lana H. Gimber, Lee Cranmer, Ali McBride and Andrew S. Kraft

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:58

    Published on:

  43. Content type: Case report

    The combination of CTLA-4 and PD-L1 inhibitors has a manageable adverse effect profile, although rare immune-related adverse events (irAE) can occur.

    Authors: Sooraj John, Scott J. Antonia, Trevor A. Rose, Robert P. Seifert, Barbara A. Centeno, Aaron S. Wagner and Ben C. Creelan

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:54

    Published on:

  44. Content type: Case report

    Spontaneous regression of metastatic melanoma and delayed responses more than one year after treatment with ipilimumab are rarely seen.

    Authors: Raphael B. Moreira, Lana Hamieh, Evisa Gjini, Ana Lako, Katherine M. Krajewski, Charles H. Yoon and Patrick A. Ott

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:61

    Published on:

  45. Content type: Case report

    The tumor microenvironment often polarizes infiltrating macrophages towards a type 2, or M2 phenotype, that is characterized by expression of various cysteine-rich, scavenger receptors, including CD163. The pr...

    Authors: Michael C. Topf, Madalina Tuluc, Larry A. Harshyne and Adam Luginbuhl

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:60

    Published on:

  46. Content type: Case report

    We report the first case to our knowledge of a patient with relapsed/refractory classical hodgkin lymphoma and liver failure with encephalopathy along with human immunodeficiency virus/acquired immunodeficienc...

    Authors: Jose D. Sandoval-Sus, Francis Mogollon-Duffo, Ankita Patel, Nathan Visweshwar, Damian A. Laber, Richard Kim and Michael V. Jagal

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:49

    Published on:

2017 Journal Metrics

Advertisement